mTOR inhibitors

mTOR inhibitors has been studied in 1,326 papers since 2002: 61 trials and 51 observational studies in people, 600 in animals, 225 in cells, 334 reviews; 324 in the past year. The newest paper, Nov 17, 2026: “Drug Repurposing of Rapamycin Mitigates Amyloid-β-Associated Proteotoxicity in Caenorhabditis elegans Models of Alzheimer's Disease”.

Intervention

1,326 papers study it1,099 more mention it2,045 findingsUpdated

PubChemMeSH

Research on it is growing about as fast as aging research as a whole: 178 papers in the latest year counted

66 new papers in 30 daysSee all 2,411 papers on mTOR inhibitors

At a glance

Independent labs report that rapamycin extends mouse lifespan and decreases cellular senescence in cells, although some senescence results point the other way. A human trial reports improved general health; another reports no clear walking-distance improvement and impaired chair stands. Some human papers declare developer ties, and companies developing these drugs sponsor trials across uses.

2,045 findings in 932 papers from 2002 to 2026, 85 of them since April 2026

Independent labs found the same change in cells, worms or flies, mice and people. 338 independent labs in 48 countries; 1,344 trials, 35 about aging, 474 with no results posted.

“angioplasty with sirolimus-coated balloons led to a lower incidence of major adverse limb events at 1 year than angioplasty with uncoated balloons”
Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery DiseaseThe New England journal of medicine2026doi:10.1056/nejmoa2600360

114 of its findings point the other way.

Cells, worms or flies, mice and humans: replicated by independent labs.
  • 338 independent labs in 48 countries
  • 114 findings against
  • 1,344 trials, 35 about aging, 474 with no results posted
  • Funders: National Institutes of Health and others
  • 223 of 1,888 findings with company ties
  • 376 of 1,344 trials sponsored by its developers
  • Human trial60
  • Humans48
  • Animals505
  • Model organisms89
  • Cells222
  • In silico35

52 studies gave mTOR inhibitors to people and measured what changed.

What changedDesignPeopleSource

up: Increases investigator's Global Assessment success72.4% versus 33.3%; adjusted relative risk 1.949 (95% CI 1.153–3.294)

down: Decreases approximate protrusion volume−61.556 units; P < .001

Randomized trial12 weeks65 peopleHyperplastic rosaceaJournal of the American Academy of Dermatology, Nov 10, 2026

up: Increases total cholesterolWeek 18 total cholesterol: 236.0 versus 219.6 mg/dl; LDL cholesterol: 151.7 versus 136.8 mg/dl; triglycerides: 159.4 versus 133.2 mg/dl

up: Increases C-reactive protein

down: Decreases hemoglobin-related parameters

Randomized trial18 weeks63 peopleALSFrontiers in pharmacology, Oct 30, 2026

up: Improves clinical response3 months: 4/5 (80%; 95% CI 28–99); 12 months: 3/4 evaluable (75%; 95% CI 19–99)

Treated cohort3 and 12 months5 peopleAdd-on treatment for active refractory iMCD-TAFROFrontiers in immunology, Oct 16, 2026

up: Increases cerebral blood flow

no change: Has no effect on cerebral blood flow

Trial4-week23 peopleaged 45 to 65 yearsCognitively normal adults aged 45 to 65 yearsJournal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, Sep 10, 2026

up: Improves exercise-induced insulin sensitivity53% on average versus placebo

Randomized trialMenbioRxiv, Sep 2, 2026

What did mouse lifespan tests of mTOR inhibitors find?

NIA ITP

The NIA Interventions Testing Program ran 4 arms from 2005 to 2015; the change in median lifespan ran from +8% to +28%.

What did other lifespan studies of mTOR inhibitors find?

DrugAge

DrugAge records 22 results from 15 papers: 8 in C. elegans, 8 in mice and 6 in D. melanogaster. Average lifespan is the mean or the median, as each paper reports it.

What did studies of mTOR inhibitors find?

543

Studies of mTOR inhibitors measured 543 outcomes; the most studied are lifespan (41 studies), cellular senescence (30) and autophagy (22).

Lifespan

upin mice10upin reviews10upin worms6upin flies5+7+81% averageHR 0.42

41 studies
  1. Rapamycin extends lifespan in worms (Aβ-expressing CL2355).

    “Rapamycin also extended Kaplan Meier survival in CL2355”

    Model organismsAβ-expressing CL235520 M

    Drug Repurposing of Rapamycin Mitigates Amyloid-β-Associated Proteotoxicity in Caenorhabditis elegans Models of Alzheimer's Disease

    bioRxivPreprint

  2. Rapamycin extends lifespan in flies (brewer's yeast medium; extended lifespan in eight experiments) (beneficial in eight experiments; neutral in 14).

    “On a nutrient-rich brewer's yeast medium favored by 4/5 strains for egg-laying, rapamycin was beneficial in eight, neutral in 14 and not significantly harmful in any experiment.”

    Model organismsbrewer's yeast medium; extended lifespan in eight experiments

    Diet-dependent, beneficial and adverse effects of rapamycin on life span of Drosophila melanogaster

    GeroScience

  3. Rapamycin shortens lifespan in flies (cornmeal/torula yeast medium; shortened lifespan in 19 experiments) (harmful in 19 experiments; no effect in 6; extended in 1).

    “On a cornmeal/torula yeast-based medium, rapamycin extended life in one experiment, had no effect in six and was harmful in 19.”

    Model organismscornmeal/torula yeast medium; shortened lifespan in 19 experiments

    Diet-dependent, beneficial and adverse effects of rapamycin on life span of Drosophila melanogaster

    GeroScience

  4. Rapamycin extends lifespan in worms (encapsulated in PEG-coated albumin nanoparticles; compared with free rapamycin) (~70% lifespan extension; outperforms free rapamycin).

    “NPA-RAP did not affect fat content but extended lifespan by ∼70%, outperforming free rapamycin.”

    Model organismsencapsulated in PEG-coated albumin nanoparticles; compared with free rapamycinPEG-coated albumin nanoparticles (NPA-RAP)

    Evaluation of Human Serum Albumin Nanoparticles for Rapamycin Delivery

    ACS omega

  5. Rapamycin extends lifespan (Evidence reviewed in model organisms; species not specified).

    “We review findings in model organisms that have revealed potent benefits of rapamycin not only for longevity”

    ReviewEvidence reviewed in model organisms; species not specified

    Bench to bedside: is rapamycin headed for the docTOR?

    GeroScience

  6. Rapamycin extends lifespan.

    “evidence that rapamycin extends lifespan, provides empirical support for the hyperfunction theory”

    Review

    A brief history of the hyperfunction theory of aging and future directions

    Aging

  7. Rapamycin extends lifespan in Eef1a2-cKO mice.

    “Early Rapamycin treatment (mTORC1 inhibition) normalizes systolic heart function and survival in Eef1a2-cKO mice”

    Animalsin Eef1a2-cKO miceheartearly treatment

    Loss of cardiomyocyte eukaryotic elongation factor 1 A2 in adult mice triggers cardiomyopathy due to defective proteostasis

    bioRxivPreprint

  8. Rapamycin extends lifespan in A. domesticus (2-week intermittent dosing from mid-age; post-treatment survival subset) (HR = 0.42).

    “Post-treatment lifespan was prolonged by rapamycin (HR = 0.42, P < 0.001)”

    Model organisms2-week intermittent dosing from mid-age; post-treatment survival subsetintermittent dosing2 weeks, intermittent

    The gerotherapeutic drugs rapamycin, acarbose, and phenylbutyrate extend lifespan and enhance healthy aging in house crickets

    Research squarePreprint

  9. Rapamycin extends lifespan in vertebrates.

    “Meta-analysis across vertebrates indicates rapamycin, unlike metformin, mirrors dietary restriction-driven lifespan extension, with a significant combined effect”

    Review

    Research Synthesis: Rapamycin Effects — full paper

    OSF Preprints (OSF Preprints)Preprint

  10. Rapamycin extends lifespan in mice Across diverse mouse stocks, ages, and dosing regimens.

    “rapamycin extends lifespan / reduces mortality in mice across diverse stocks, ages, and dosing regimens.”

    ReviewAcross diverse mouse stocks, ages, and dosing regimens

    Rapamycin extends lifespan / reduces mortality in mice across diverse stocks, ages, and dosing regimens

    Preprint

All 49

Cellular senescence

downin human cells12downin cells4downin mice3downin mouse cells3+6

30 studies
  1. Rapamycin decreases cellular senescence in vivo.

    “Overall, these results suggest that rapamycin reduces the expression of immune exhaustion markers, and p21, a marker of both persistent DNA damage and cell senescence.”

    Human trialin vivo4 monthsmales

    Rapamycin Exerts Its Geroprotective Effects in the Ageing Human Immune System by Enhancing Resilience Against DNA Damage

    Aging cell

  2. Rapamycin was not clearly linked with cellular senescence in humans (at target GVHD-prophylaxis doses, compared with cyclosporine plus MMF cohort).

    “neither expression of senescence markers nor the abundance of SASP factors differed significantly in the sirolimus treated cohort compared to cyclosporine control cohort”

    Humansat target GVHD-prophylaxis doses, compared with cyclosporine plus MMF cohorttarget doses to reduce GVHD risk

    Sirolimus use in allogeneic hematopoietic cell transplant recipients: assessing its senotherapeutic role in a high risk population

    Frontiers in aging

  3. mTOR inhibitors decrease cellular senescence in human cells (SEPTIN6 germline mutation models).

    “pharmacologic inhibition of the mTOR pathway resulted in rescue of senescence.”

    CellsSEPTIN6 germline mutation modelshematopoietic stem and progenitor cells

    Gene variants made human blood-forming cells stop dividing early

    JCI insight

  4. Rapamycin decreases cellular senescence in aged atherosclerotic mice.

    “aortic leukocytes displayed profoundly reduced senescent enrichment scores”

    Animalsin aged atherosclerotic miceaorta8 weeksmales

    Rapamycin reduced plaque inflammation in aged mice

    Aging cell

  5. Rapamycin decreases cellular senescence in rat cells (IL-1β or MIDN overexpression-induced).

    “mTORC1 inhibition (Rapamycin) significantly attenuated IL-1β or MIDN overexpression-induced senescence and disc degeneration.”

    CellsIL-1β or MIDN overexpression-inducednucleus pulposus cells

    Impaired Chaperone-Mediated Autophagy Accelerates Intervertebral Disc Degeneration by Inducing MIDN Accumulation to Target TSC2 for Proteasomal Degradation

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)

  6. Rapamycin decreases cellular senescence in rat cells.

    “suppressing NP cell senescence-related phenotypes (morphological changes, elevated IL-1β/TNF-α secretion, increased β-gal activity, lysosomal dysfunction, upregulated P21/P16 and reduced P27 expression)”

    Cellsnanoliposomesnucleus pulposus cells

    Rapamycin-nanoliposomes target the mTORC1-mediated autophagy-lysosomal and NLRP3/Caspase-1 pathways to inhibit nucleus pulposus cell senescence in intervertebral discs

    Bioengineering & translational medicine

  7. Rapamycin increases cellular senescence in female Lcn2 knockout cells.

    “Blocking mTOR activation with Rapamycin led to increased senescence in female Lcn2 KO cells.”

    Cellsin female Lcn2 knockout cellsinguinal fatfemales

    Sex-Specific Regulation of Adipose Progenitor Cell Senescence by Lipocalin 2 via Phosphatidic Acid–Dependent mTOR Signaling Pathway

    ADA Scientific Sessions 2026 abstract

  8. Rapamycin decreases cellular senescence in Eif4a2-deleted tumours.

    “reduction of mRNA translation with rapamycin in Eif4a2-deleted tumours suppresses senescence and restores tumorigenesis”

    Animalsin Eif4a2-deleted tumours

    Increased mRNA translation delays tumour initiation and exposes a therapeutic vulnerability in lung cancer

    Molecular cancer

  9. Rapamycin decreases cellular senescence in young hEnSCs exposed to conditioned medium from BPS-treated senescent cells.

    “Rapa can inhibit the senescence of young cells induced by the culture medium of senescent cells treated with BPS”

    Cellsin young hEnSCs exposed to conditioned medium from BPS-treated senescent cells

    Autophagy attenuates the secondary senescence of endometrial stromal cells induced by Bisphenol S

    Chemico-biological interactions

  10. Rapamycin decreases cellular senescence in mice.

    “One month of rapamycin treatment effectively suppressed mTOR signaling and reduced cellular senescence, inflammation, fibrosis, and oxidative damage in the ovary, lung, small intestine, and skeletal muscle.”

    Animalsovary, lung, small intestine, skeletal muscleone month

    Short-Term Rapamycin Mitigates the Senescence of Ovaries and Somatic Stem Cells in Multiple Organs in Reproductively Aged Mice

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

All 31

More on Cellular senescence

Autophagy

upin mice6upin human cells5upin reviews5downin bovine cells1+5

22 studies
  1. Rapamycin activates autophagy in human cells.

    “At the molecular level, rapamycin suppressed mTOR expression and increased the mRNA and protein expression of Beclin-1 and LC3B, indicating activation of autophagy-related signaling.”

    Cellsfacial skin fibroblasts0.1 nmol/L48 hfemales

    Rapamycin Alleviates Age-Related Senescence in Human Facial Dermal Fibroblasts by Modulating Autophagy

    Research SquarePreprint

  2. Rapamycin activates autophagy in murine DSS colitis.

    “Finally, enteric rapamycin administration reduced ER stress and restored autophagy in murine DSS colitis.”

    Animalsin murine DSS colitiscolon

    Autophagy prevents ER stress-induced Tight Junction barrier disruption via claudin-2 homeostasis

    bioRxiv : the preprint server for biologyPreprint

  3. Rapamycin induces autophagy.

    “Inhibition of the mTORC1 protein complex with low doses of rapamycin initiates autophagy in the skin.”

    Reviewskinlow doses

    Epigenetic and chronopharmacological modulation of cellular aging in the skin

    Medical and Clinical Chemistry

  4. Rapamycin activates autophagy in ketogenic diet and ovariectomy cohorts.

    “It upregulated OCN, ALP, RUNX2, LC3-II/LC3-I, Beclin1, and ATG7 and downregulated TRAP, PPARγ, p-mTOR, and P62 in the KD and OVX cohorts.”

    Animalsin ketogenic diet and ovariectomy cohorts

    Ketogenic Diet Might Regulate Autophagy of BMSCs via mTOR Signaling Contributing to Osteoporosis in Mice

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

  5. Rapamycin activates autophagy in mouse cells (imidazole propionate exposure).

    “the mechanistic target of rapamycin (mTOR) inhibitor rapamycin (Rap) restores autophagy”

    Cellsimidazole propionate exposurerenal tubular epithelial cell

    Imidazole Propionate Induces Kidney Damage by Activating the ROS-NLRP3 Signaling Pathway Through mTOR Inhibition of Autophagy in Renal Tubular Epithelial Cells

    Mediators of inflammation

  6. Rapamycin increases autophagy in mice (phenocopied the CR effects on autophagy flux).

    “Rapamycin phenocopied the CR effects on flux and signaling, whereas 3-MA reversed them.”

    Animalsphenocopied the CR effects on autophagy fluxmales

    Maladaptive autophagy mediates renal fibrosis under caloric restriction in aristolochic acid nephropathy

    International immunopharmacology

  7. mTOR inhibitors activate autophagy.

    “mTOR or caloric-restriction mimetics jump-start a protective flux”

    Review

    Autophagy and mitophagy in dermatological disease: a comprehensive review from molecular pathways to therapeutic frontiers

    Biology direct

  8. Rapamycin activates autophagy (via suppression of mTOR signalling in preclinical studies).

    “Preclinical studies have shown that rapamycin can stimulate autophagic pathways by suppressing mTOR signalling, leading to increased expression of autophagy markers.”

    Reviewvia suppression of mTOR signalling in preclinical studies

    Rapamycin and Autophagy: Potential Therapeutic Approach for Parkinson's Disease Treatment

    CNS & neurological disorders drug targets

  9. Rapamycin increases autophagy.

    “In vitro studies demonstrated that rapamycin enhances osteogenic differentiation, upregulates autophagy, suppresses inflammatory cytokines, and delays cellular senescence.”

    Review

    Rapamycin's Role in Periodontal Health and Therapeutics: A Scoping Review

    JDR clinical and translational research

  10. mTOR inhibitors activate autophagy.

    “mammalian target of rapamycin (mTOR) inhibitors have shown anti-aging effects by promoting autophagy and inhibiting proinflammatory pathways.”

    Review

    Kidney Disease as a Driver of Immunosenescence: Mechanisms and Potential Interventions

    Journal of the American Society of Nephrology : JASN

All 22

More on Autophagy

mTOR signaling

downin mice5downin reviews3downin human cells2downin humans2+4

16 studies
  1. Rapamycin inhibits mTOR signaling in mice (muscle-specific Depdc5 knockout).

    “Dietary rapamycin partially reversed mTORC1 signaling”

    Animalsmuscle-specific Depdc5 knockoutskeletal muscle

    Growth signaling raises inflammatory gene activity in old mice

    Aging cell

  2. Rapamycin inhibits mTOR signaling in vitro.

    “In vitro, encapsulated rapamycin retained mTOR-inhibitory activity”

    Cellsin vitroencapsulated

    19F MRI-Traceable PLGA Nanocarriers: Influence of Particle Architecture on Co-Encapsulation and Release of Immiscible Payloads

    ACS biomaterials science & engineering

  3. Rapamycin inhibits mTOR signaling in humans (detected in glioblastoma brain tissue).

    “direct tissue sampling in glioblastoma detects rapamycin in brain at mTORC1-inhibitory concentrations”

    Reviewdetected in glioblastoma brain tissuebrain

    Beyond the cerebrospinal fluid: Preclinical and clinical evidence on central nervous system penetration and functional activity of oral rapamycin (sirolimus)

    Journal of Alzheimer's disease : JAD

  4. Rapamycin inhibits mTOR signaling in rat cells.

    “rapa-lipos targeted-inhibited mTORC1”

    Cellsnanoliposomesnucleus pulposus cells

    Rapamycin-nanoliposomes target the mTORC1-mediated autophagy-lysosomal and NLRP3/Caspase-1 pathways to inhibit nucleus pulposus cell senescence in intervertebral discs

    Bioengineering & translational medicine

  5. Rapamycin inhibits mTOR signaling in DEPDC5 KO mice.

    “These mTORC1-driven signaling effects were partially reversed by rapamycin treatment.”

    Animalsin DEPDC5 KO miceskeletal muscle

    Rapamycin Reverses mTORC1-Driven Suppression of Angiogenic Gene Expression in Aged Mouse Skeletal Muscle

    Physiology

  6. Rapamycin inhibits mTOR signaling.

    “micro-dose rapamycin inhibits mTORC1”

    Reviewmicro-dose

    Autophagy enhancement via metformin-rapamycin combination for Z-AAT clearance

    Zenodo (CERN European Organization for Nuclear Research)Preprint

  7. Rapamycin inhibits mTOR signaling in humans (Hutchinson–Gilford progeria syndrome).

    “Rapamycin inhibits mTORC1 signaling”

    ReviewHutchinson–Gilford progeria syndromeHGPS cells

    Rapamycin mTOR Inhibition for Progeria Cellular Senescence

    Zenodo (CERN European Organization for Nuclear Research)Preprint

  8. Rapamycin inhibits mTOR signaling in mice.

    “One month of rapamycin treatment effectively suppressed mTOR signaling”

    Animalsone month

    Short-Term Rapamycin Mitigates the Senescence of Ovaries and Somatic Stem Cells in Multiple Organs in Reproductively Aged Mice

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology

  9. Rapamycin inhibits mTOR signaling in Kptn-/- mice.

    “Kptn-/- mice exhibited increased cortical mTOR signaling that was reduced by rapamycin.”

    Animalsin Kptn-/- micecortex

    The Clinical Spectrum and Neurodevelopmental Pathogenesis of KPTN-Related Disorder in a Mouse Model

    Annals of neurology

  10. Rapamycin inhibits mTOR signaling in mice (frequent dosing (3x/week) during PoWeR).

    “Frequent but not intermittent rapamycin suppressed skeletal muscle mTORC1 signaling in PoWeR trained mice.”

    Animalsfrequent dosing (3x/week) during PoWeRfrequent dosing (2mg/kg, 3x/week)skeletal muscle2mg/kg8 weeksfemales

    Rapamycin does not compromise physical performance or muscle hypertrophy after PoWeR while intermittent rapamycin alleviates glucose disruptions by frequent rapamycin

    bioRxiv : the preprint server for biologyPreprint

All 16

More on mTOR signaling

Inflammation

downin human cells3downin humans2downin reviews2downin mice1+2

10 studies
  1. Rapamycin decreases inflammation in humans (APOE4 carriers).

    “shows that the E4(+) group exhibited significant post-treatment reductions in monocyte chemoattractant protein-1 (MCP-1), a key mediator of inflammation and tissue injury (−0.155; 95% CI: −0.307, −0.003, p = 0.046).”

    Human trialAPOE4 carriers4-weekn = 9

    Rapamycin increases brain blood flow in Alzheimer's gene carriers

    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism

  2. Rapamycin decreases inflammation in APOE4 carriers.

    “shows that the E4(+) group experienced significant post-treatment reductions in monocyte chemoattractant protein-1 (MCP-1), a key regulator of inflammation and tissue damage.”

    Human trialin APOE4 carriers4 weeksn = 9

    Rapamycin enhances neurovascular, peripheral metabolic, and immune function in cognitively normal, middle-aged APOE4 Carriers: genotype-dependent effects compared to non-carriers

    Research squarePreprint

  3. Rapamycin decreases inflammation.

    “Metabolic modulators such as metformin and rapamycin attenuate inflammatory signaling”

    Review

    Inflammaging: Experimental Insights and Translational Advances

    European journal of immunology

  4. Rapamycin decreases inflammation in mouse cells.

    “Rapamycin could activate the nuclear translocation of TFE3 and enhance phagocytosis and alleviate inflammation of microglia.”

    Cellsmicroglia

    TFE3 Regulates Microglial Phagocytosis and Inflammation in MPTP-induced Parkinson's Disease

    Molecular neurobiology

  5. Rapamycin decreases inflammation in imiquimod-treated HaCaT cells.

    “It also reduced cytokine expression and promoted the recovery of filaggrin expression.”

    Cellsin imiquimod-treated HaCaT cellskeratinocyte

    A SFPQ/S100A8 Complex Is Formed by Activation of mTOR-p70S6K Pathway in Psoriasis

    Journal of Experimental & Biomedical Sciences/Biomedical Science Letters

  6. Rapamycin decreases inflammation in LPS-stimulated hiPSC-derived oral keratinocytes in GEoC platform.

    “demonstrated by differential cytokine attenuation following rapamycin and stannous fluoride treatment”

    Cellsin LPS-stimulated hiPSC-derived oral keratinocytes in GEoC platform

    hiPSC-Derived Gingival Epithelium-On-Chip for Modeling Inflammation and Immune Response

    ACS applied materials & interfaces

  7. Rapamycin decreases inflammation in mice (ozone-exposed mice).

    “The mTOR inhibitor rapamycin improved the emphysema index and inflammation scores in mice lung tissue.”

    Animalsozone-exposed micelung

    The mTOR Inhibitor Rapamycin Attenuates Ozone-Induced Airway Inflammation and Emphysema In Mice

    Journal of inflammation research

  8. mTOR inhibitors decrease inflammation in human cells.

    “together with decreased inflammatory signaling”

    Cellsinduced pluripotent stem cell-derived vascular smooth muscle cells

    Targeting Vascular Aging in Progeria by mTOR Inhibitors from Multi-Omics Screening

    GSA 2025 abstract

  9. Rapamycin increases inflammation in mice (experimental pneumococcal meningitis).

    “sirolimus treatment increased inflammation”

    Animalsexperimental pneumococcal meningitis

    mTORC1 inhibition by sirolimus as adjunctive treatment in experimental pneumococcal meningitis

    Brain communications

  10. Rapamycin decreases inflammation.

    “Animal studies confirmed rapamycin's role in alveolar bone preservation, inhibition of biofilm formation, immune modulation, and periodontal inflammation attenuation.”

    Reviewperiodontal tissue

    Rapamycin's Role in Periodontal Health and Therapeutics: A Scoping Review

    JDR clinical and translational research

More on Inflammation

Apoptosis

downin cells1no changein human cells1downin human cells1downin marmosets1+3

7 studies
  1. Rapamycin decreases apoptosis in rats (renal ischemia–reperfusion injury).

    “Rapamycin treatment significantly reduced tubular injury and apoptosis following renal I/R injury.”

    Animalsrenal ischemia–reperfusion injurykidney1 or 2 mg/kg dailymale and femalesn = 6

    Rapamycin attenuates renal ischemia–reperfusion injury and early profibrotic responses

    Scientific reports

  2. Rapamycin decreases apoptosis in marmosets (aging submandibular gland).

    “a reduction in fibrosis, lipid accumulation, and number of apoptotic and senescent cells”

    Animalsaging submandibular glandsubmandibular glandchronic

    Rapamycin Attenuates Age-Related Changes in Marmoset Submandibular Gland: A Non-Human Primate Model of Human Oral Aging

    Aging and disease

  3. mTOR inhibitors showed no clear effect on apoptosis in human cells.

    “without induction of apoptosis”

    Cellsinduced pluripotent stem cell-derived vascular smooth muscle cells

    Targeting Vascular Aging in Progeria by mTOR Inhibitors from Multi-Omics Screening

    GSA 2025 abstract

  4. Rapamycin prevents apoptosis in mouse cells (high glucose-induced).

    “rapamycin prevented HG-induced apoptosis by inhibiting mTOR activation and promoting autophagy”

    Cellshigh glucose-induced

    Reactive Oxygen Species (ROS) Drive Osteocyte Dysfunction in Diabetic Osteoporosis by Impairing Autophagy and Triggering Apoptosis

    Antioxidants (Basel, Switzerland)

  5. Temsirolimus decreases apoptosis in human cells (IL-1β-induced).

    “Temsirolimus treatment protected human chondrocytes from IL-1β-induced OA gene expression changes and apoptosis.”

    CellsIL-1β-induced

    Temsirolimus, a water-soluble mTOR inhibitor, alleviates osteoarthritic changes in human chondrocytes and mouse osteoarthritis models

    Connective tissue research

  6. Rapamycin prevents apoptosis in mice (aging-induced apoptosis).

    “prevented aging-induced apoptosis of acinar cells”

    Animalsaging-induced apoptosisacinar cellmales

    PINK1/Parkin-Mediated Mitophagy Ameliorates Mitochondrial Dysfunction in Lacrimal Gland Acinar Cells During Aging

    Investigative ophthalmology & visual science

  7. Rapamycin decreases apoptosis in cells (placental MSC sheet culture).

    “Rapamycin also significantly decreased the number of cells in late apoptosis at day 7 of sheet culture”

    Cellsplacental MSC sheet cultureday 7

    Rapamycin Inhibits Senescence and Improves Immunomodulatory Function of Mesenchymal Stem Cells Through IL-8 and TGF-β Signaling

    Stem cell reviews and reports

More on Apoptosis

Survival

upin mice4downin flies1no changein mice1

6 studies
  1. Rapamycin increases survival in mice (pretreatment before 8 Gy total body irradiation).

    “Rapamycin pretreatment improved survival and reduced markers of intestinal injury following 8 Gy total body irradiation (TBI)”

    Animalspretreatment before 8 Gy total body irradiation

    Targeting Autophagy Accelerates Intestinal Repair after Acute Ionizing Radiation

    Frontiers in physiology

  2. Rapamycin increases survival in mice (endothelial TIE2 L914F mutant mice).

    “Targeted treatment with rapamycin partially reduces lesion growth by targeting increased proliferation and prolongs mouse survival”

    Animalsendothelial TIE2 L914F mutant mice

    An endothelial-specific TIE2-L914F mouse model reveals cellular mechanisms of venous malformation progression and recapitulates the patient's response to targeted therapy

    bioRxivPreprint

  3. Rapamycin increases survival in mice (oncogene-induced senescence model).

    “Rapamycin administration attenuates senescence-associated features and improves survival.”

    Animalsoncogene-induced senescence model

    Cancer-promoting signals and immunity shape cell clearance in mice

    Nature communications

  4. Rapamycin showed no clear effect on survival in mice (experimental pneumococcal meningitis).

    “sirolimus treatment did not improve survival”

    Animalsexperimental pneumococcal meningitis

    mTORC1 inhibition by sirolimus as adjunctive treatment in experimental pneumococcal meningitis

    Brain communications

  5. Rapamycin impairs survival in POLγexo- larvae.

    “Treating POLγexo- larvae with the autophagy activator rapamycin aggravates their lethal phenotype”

    Model organismsin POLγexo- larvae

    Preventing excessive autophagy protects from the pathology of mtDNA mutations in Drosophila melanogaster

    Nature communications

  6. Rapamycin increases survival in mice (all rapamycin-treated mice survived vs 43% of controls died).

    “All mice administered rapamycin survived the 12-week course, whereas 43% of the controls died.”

    Animals1.5 mg/kg/week12 weeks

    Rapamycin treatment increases survival, autophagy biomarkers and expression of the anti-aging klotho protein in elderly mice

    Pharmacology research & perspectives

Cognitive function

upin mice2upin rats2no changein humans1upin rodents1

6 studies
  1. Rapamycin showed no clear effect on cognitive function in humans.

    “there are no significant cognitive changes”

    Human trial1 mg/dayeight weeksn = 10

    Rapamycin treatment for Alzheimer's disease and related dementias: a pilot phase 1 clinical trial

    Communications medicine

  2. Rapamycin improves cognitive function in rats (right-sided insular cortex ischemic stroke).

    “pharmacological activation of autophagy with rapamycin restored RVLM activity, normalized blood pressure, and improved cognitive performance.”

    Animalsright-sided insular cortex ischemic strokemales

    Rapamycin improves memory and blood pressure stability in asymmetrical cortico-brainstem connectivity following stroke

    Brain research bulletin

  3. Rapamycin improves cognitive function in 5xFAD and hAPPNL mice.

    “These pathological improvements were associated with attenuated deficits in hippocampal-dependent memory tasks”

    Animalsin 5xFAD and hAPPNL miceoralhippocampus

    Rapamycin Reduces Amyloid-β Plaques and Improves Behavioral Performance in a Sex-Dependent Manner in Mouse Models of Amyloidosis

    CNS neuroscience & therapeutics

  4. Rapamycin improves cognitive function in melamine cyanurate-exposed adolescent rats.

    “up-regulation of autophagy by rapamycin could effectively alleviate cognitive deficits and synaptic dysfunction”

    Animalsin melamine cyanurate-exposed adolescent ratshippocampus

    Chronic melamine cyanurate exposure impairs spatial learning and memory by altering autophagy-mediated synaptic plasticity and oxidative stress in the hippocampus of adolescent rats

    Archives of toxicology

  5. Rapamycin improves cognitive function in rodent models of AD.

    “Rapamycin and metformin restore autophagic flux, reduce Aβ and tau pathologies, and improve memory.”

    Reviewin rodent models of AD

    Autophagy and Cellular Senescence in Alzheimer's Disease: Key Drivers of Neurodegeneration

    CNS neuroscience & therapeutics

  6. Rapamycin improves cognitive function in mice (older mice undergoing anesthesia and surgery) (β 54.51, 95% CI 6.77–102.25).

    “improved cognitive performance at 1-week postoperatively (β 40.18, 95%C.I. 8.70-71.67, p = 0.012), but only in older mice (β 54.51, 95%C.I. 6.77-102.25, p = 0.025).”

    Animalsolder mice undergoing anesthesia and surgery1 week postoperatively after 8 weeks of preoperative treatmentn = 20

    Effect of preoperative rapamycin supplementation on perioperative clinical frailty and cognitive performance in a murine model undergoing anesthesia and surgery

    Scientific reports

Healthspan

upin reviews3upin mice2

5 studies
  1. Rapamycin improves healthspan (through mTOR inhibition).

    “as well as for promoting healthspan”

    Reviewthrough mTOR inhibition

    Rapamycin across biology and medicine: From molecular mechanisms to clinical and translational frontiers

    Biochimica et biophysica acta. General subjects

  2. Rapamycin improves healthspan in Ythdf1-depleted mice.

    “Rapamycin restored murine healthspan in contrast to the maximum lifespan shortening caused by Ythdf1 depletion.”

    Animalsin Ythdf1-depleted mice

    YTHDF1 differentiates the contributing roles of mTORC1 in aging

    Molecular cell

  3. Rapamycin improves healthspan (preclinical studies cited as background).

    “Sirolimus (rapamycin) , an mTOR inhibitor, has shown potential in preclinical studies to extend lifespan and improve health span.”

    Reviewpreclinical studies cited as background

    A single-center, double-blind, randomized, placebo-controlled, two-arm study to evaluate the safety and efficacy of once-weekly sirolimus (rapamycin) on muscle strength and endurance in older adults following a 13-week exercise program

    Trials

  4. Rapamycin improves healthspan in mice (continuous feeding compared with intermittent feeding).

    “chronic treatment is more beneficial to healthspan”

    Animalscontinuous feeding compared with intermittent feeding42 mg/kg

    Intermittent rapamycin feeding recapitulates some effects of continuous treatment while maintaining lifespan extension

    Molecular metabolism

  5. Rapamycin improves healthspan.

    “Inhibition of the protein kinase mechanistic target of rapamycin (mTOR) with the Food and Drug Administration (FDA)-approved therapeutic rapamycin promotes health and longevity in diverse model organisms.”

    Review

    Targeting the biology of aging with mTOR inhibitors

    Nature aging

Mortality

no changein humans3downin flies1RR 0.98

4 studies
  1. Rapamycin showed no clear effect on mortality in humans (primary safety outcome, death from any cause within 1 year) (risk difference -1.0 percentage points (95% CI -4.6 to 2.7); P = 0.67).

    “Death occurred in 74 patients (11.8%) in the sirolimus-coated-balloon group and in 80 patients (12.8%) in the uncoated-balloon group”

    Human trialprimary safety outcome, death from any cause within 1 yearsirolimus-coated balloon1 yearn = 1,252

    Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery Disease

    The New England journal of medicine

  2. Rapamycin showed no clear effect on mortality in-stent restenosis (RR: 0.98; p = 0.96).

    “In contrast, both platforms demonstrated no differences in all-cause mortality (RR: 0.98; p = 0.96)”

    Reviewin-stent restenosis

    Limus- Versus Paclitaxel-Coated Balloons for In-Stent Restenosis Treatment: A Systematic Review and Study-Level Meta-Analysis of Randomized Controlled Trials

    The American journal of cardiology

  3. Rapamycin showed no clear effect on mortality in humans (coronary in-stent restenosis).

    “No significant differences were observed for mortality, TVMI, binary restenosis, LLL, diameter stenosis, or MLD”

    Reviewcoronary in-stent restenosisn = 988

    Drug-coated balloons in coronary in-stent restenosis: a systematic review and meta-analysis comparing sirolimus and biolimus with paclitaxel platforms

    Cardiovascular intervention and therapeutics

  4. Rapamycin decreases mortality in TBI-injured young flies, 24 hours post-injury.

    “mortality at 24 hours post-injury in young flies was significantly reduced by pharmacological inhibition of TOR with rapamycin or RapaLink-1”

    Model organismsin TBI-injured young flies, 24 hours post-injury24 hours post-injury

    Aging influences nucleolar responses to traumatic brain injury in Drosophila

    PloS one

Total cholesterol

upin humans3

3 studies
  1. Rapamycin increases total cholesterol in humans (ALS; compared with placebo) (Week 18 total cholesterol: 236.0 versus 219.6 mg/dl; LDL cholesterol: 151.7 versus 136.8 mg/dl; triglycerides: 159.4 versus 133.2 mg/dl).

    “In the rapamycin-treated patients, total and LDL cholesterol, and triglycerides rose compared to placebo”

    Human trialALS; compared with placebo1 or 2 mg/m2/day18 weeksn = 63

    Metabolic effects of Rapamycin in Amyotrophic Lateral Sclerosis patients: secondary analysis of an RCT

    Frontiers in pharmacology

  2. Everolimus increases total cholesterol in humans during everolimus treatment in TSC-RAML patients.

    “Aspartate transaminase (AST), Alanine transferase (ALT), total cholesterol (TC), and triglyceride (TG) increased significantly during everolimus treatment (P < 0.05)”

    Human trialduring everolimus treatment in TSC-RAML patientsyear-long

    The impact of everolimus on hematologic parameters in patients with renal angiomyolipoma associated with tuberous sclerosis complex

    Discover oncology

  3. Rapamycin analogs increase total cholesterol in individuals with ageing-related diseases.

    “there were increased numbers of infections and increases in total cholesterol, LDL cholesterol, and triglycerides in individuals with ageing-related diseases”

    Reviewin individuals with ageing-related diseases

    Targeting ageing with rapamycin and its derivatives in humans: a systematic review

    The lancet. Healthy longevity

More on Total cholesterol

Adverse events

upin humans2no changein humans1

3 studies
  1. Rapamycin increases adverse events in humans (adverse-event monitoring) (99 vs. 63 events).

    “the total burden was higher with sirolimus (99 vs. 63 events)”

    Human trialadverse-event monitoring6 mg once weekly13 weeks

    Exercise and Weekly Sirolimus (Rapamycin) in Older Adults: RAPA-EX-01 Randomised, Double-Blind, Placebo-Controlled Trial

    Journal of cachexia, sarcopenia and muscle

  2. Rapamycin increases adverse events in humans (twenty adverse events, mostly mild).

    “After treatment, we find that twenty, mostly mild adverse events occur”

    Human trial1 mg/dayeight weeksn = 10

    Rapamycin treatment for Alzheimer's disease and related dementias: a pilot phase 1 clinical trial

    Communications medicine

  3. Rapamycin showed no clear effect on adverse events in humans.

    “Adverse and serious adverse events were similar across all groups.”

    Human trial5 mg or 10 mg weekly48 weeks

    Safety and efficacy of rapamycin on healthspan metrics after one year: PEARL Trial Results

    medRxivPreprint

Senescence-associated secretory phenotype (SASP)

upin cells1downin humans1downin mice1

3 studies
  1. Rapamycin inhibits senescence-associated secretory phenotype (SASP) in humans.

    “Given that p16 and COX2 play a key role in cellular senescence and inflammation respectively, their significant reduction after sirolimus treatment appears to indicate an attenuated SASP and inflammatory response, which should contribute to the anti-malignant activity of sirolimus.”

    Human trial5–7 daysfemalesn = 27

    mTOR inhibition abrogates human mammary stem cells and early breast cancer progression markers

    Breast cancer research : BCR

  2. Rapamycin increases senescence-associated secretory phenotype (SASP) in cells (upon discontinuation of rapamycin treatment in high-passage senescent cells).

    “discontinuation of which results in robust but selective senescent enhancer activation and exacerbation of the SASP”

    Cellsupon discontinuation of rapamycin treatment in high-passage senescent cells

    Ligand-specific regulation of a binary enhancer code dictating cellular senescence

    Proceedings of the National Academy of Sciences of the United States of America

  3. Rapamycin decreases senescence-associated secretory phenotype (SASP) in mice (STAM mice, sirolimus-administered groups compared with placebo).

    “Protein levels of some SASP factors (TNFα, IL1β, IL-2, CXCL15) were significantly lower in sirolimus administered groups compared to placebo group.”

    AnimalsSTAM mice, sirolimus-administered groups compared with placeboliver

    Role of hepatocellular senescence in the development of hepatocellular carcinoma and the potential for therapeutic manipulation

    Human cell

More on Senescence-associated secretory phenotype (SASP)

Cerebral blood flow

no changein humans2upin humans2

2 studies
  1. Rapamycin showed no clear effect on cerebral blood flow in APOE4 non-carriers.

    “In contrast, non-carriers showed no significant change in CBF”

    Human trialin APOE4 non-carriersbrain1 mg/day4 weeksn = 14

    Rapamycin increases brain blood flow in Alzheimer's gene carriers

    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism

  2. Rapamycin increases cerebral blood flow in APOE4 carriers (>15% increase across multiple brain regions).

    “Rapamycin significantly increased CBF in APOE4 carriers, with increases exceeding 15% across multiple brain regions”

    Human trialin APOE4 carriersbrain1 mg/day4 weeksn = 9

    Rapamycin increases brain blood flow in Alzheimer's gene carriers

    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism

  3. Rapamycin increases cerebral blood flow in humans (APOE4 carriers).

    “After 4 weeks of rapamycin treatment, CBF was increased in the overall study sample (3.08; 95% CI: 0.16, 6.00, p = 0.04), particularly E4(+) participants, who showed a significant increase in CBF (4.68; 95% CI: 0.003, 9.36, p = 0.05).”

    Human trialAPOE4 carriers4-weekn = 9

    Rapamycin increases brain blood flow in Alzheimer's gene carriers

    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism

  4. Rapamycin showed no clear effect on cerebral blood flow in APOE4 non-carriers (E4(-)).

    “non-carriers (E4(-)) displayed stable baseline-to-post-treatment CBF and SCFA”

    Human trialin APOE4 non-carriers (E4(-))low-dosebrain1mg/day4-week

    Rapamycin enhances neurovascular, peripheral metabolic, and immune function in cognitively normal, middle-aged APOE4 Carriers: genotype-dependent effects compared to non-carriers

    Research squarePreprint

  5. Rapamycin increases cerebral blood flow in humans (open-label trial, relative to baseline).

    “significantly improved cerebral blood flow (CBF) relative to baseline in cognitively normal APOE4 carriers (E4(+)) aged 45-65”

    Human trialopen-label trial, relative to baselinelow-dosebrain1mg/day4-week

    Rapamycin enhances neurovascular, peripheral metabolic, and immune function in cognitively normal, middle-aged APOE4 Carriers: genotype-dependent effects compared to non-carriers

    Research squarePreprint

  6. Rapamycin improves cerebral blood flow in APOE4 carriers (>15%).

    “Results indicate that the Rapamycin regimen significantly increased CBF in APOE4 carriers (E4(+)). displays CBF maps for both E4(+) and E4(−) before and after the intervention, with the color bar representing CBF values from 0 to 65 ml/100g/min on a linear scale.”

    Human trialin APOE4 carriers4 weeksn = 9

    Rapamycin enhances neurovascular, peripheral metabolic, and immune function in cognitively normal, middle-aged APOE4 Carriers: genotype-dependent effects compared to non-carriers

    Research squarePreprint

Cerebral blood flow

upin humans2

2 studies
  1. Rapamycin increases cerebral blood flow in APOE4 carriers in the prevention trial.

    “APOE4 carriers demonstrated reduced plasma cytokines and increased cerebral blood flow at post-treatment (all p < 0.05)”

    Human trialin APOE4 carriers in the prevention trialbrain1 mg/day4-12 weeksn = 9

    Stage-Dependent Effects of Rapamycin for Alzheimer’s Disease: Insights from Prevention and Treatment Trials

    GSA 2025 abstract

  2. Rapamycin increases cerebral blood flow in APOE4 carriers.

    “increased cerebral blood flow in APOE4 carriers”

    Reviewin APOE4 carriersbrain

    Beyond the cerebrospinal fluid: Preclinical and clinical evidence on central nervous system penetration and functional activity of oral rapamycin (sirolimus)

    Journal of Alzheimer's disease : JAD

More on Cerebral blood flow

All 543

What is mTOR inhibitors linked with?

31

Studies link mTOR inhibitors with 31 measures, among them FST/ITGA1 ratio, NETosis-associated markers and inflammatory monocyte and B cell abundance.

FST/ITGA1 ratio

mixedin silico1

1 study
  1. Rapamycin is associated with FST/ITGA1 ratio in silico (senescence).

    “it identified FST/ITGA1 as a rapamycin-sensitive senescence-associated ratio”

    In silicosenescencefibroblast

    Framework maps aging-related states in connective tissue cells

    bioRxivPreprint

More on FST/ITGA1 ratio

NETosis-associated markers

downin mice1

1 study
  1. Rapamycin is associated with NETosis-associated markers in mice (bone cancer pain mouse model).

    “rapamycin treatment was associated with reduced levels of NETosis-associated markers, including NE, MPO, and citrullinated histone H3, in the spinal cord.”

    Animalsbone cancer pain mouse modelspinal cord5 mg/kg

    Rapamycin attenuates bone cancer pain and tumor progression associated with reduced NE/NETosis-related molecular signatures in a mouse model

    International immunopharmacology

More on NETosis-associated markers

Inflammatory monocyte and B cell abundance

downin humans1

1 study
  1. Rapamycin is associated with inflammatory monocyte and B cell abundance in humans (TAFRO-phenotype patient receiving add-on treatment; exploratory paired analysis).

    “Exploratory paired single-cell RNA sequencing in one TAFRO-phenotype patient showed reductions in inflammatory monocytes and B cells with lower cytotoxic and proliferative programs.”

    Human trialTAFRO-phenotype patient receiving add-on treatment; exploratory paired analysis1–2 mg/dayn = 1

    Add-on sirolimus in refractory iMCD-TAFRO: a TAFRO-enriched 8-patient case series with paired single-cell profiling

    Frontiers in immunology

More on Inflammatory monocyte and B cell abundance

Serum cytokines

mixedin dogs1

1 study
  1. Rapamycin is associated with serum cytokines in dogs (90-day intervention, endpoint cytokine measurements).

    “Rapamycin was associated with the broadest endpoint cytokine response.”

    Animals90-day intervention, endpoint cytokine measurements90 daysn = 24

    Sex-stratified immune patterns across the canine lifespan and short-term responses to geroprotective interventions

    Biogerontology

More on Serum cytokines

Serum cytokine responses

mixedin dogs1

1 study
  1. Rapamycin is associated with serum cytokine responses in dogs (exploratory; small group sizes, endpoint-only measurements).

    “Rapamycin was associated with the broadest endpoint cytokine response.”

    Animalsexploratory; small group sizes, endpoint-only measurements90 daysn = 24

    Sex-dimorphic immune trajectories across the canine lifespan and early-life signatures of geroprotective interventions

    bioRxivPreprint

More on Serum cytokine responses

ULK1

mixedin silico1

1 study
  1. Rapamycin is associated with ULK1 in silico hypergraph inference, not tested experimentally (Sc=0.4703, novel).

    “Rapamycin -> ULK1 Kinase (Sc=0.4703Sc=0.4703 - Novel / Resolved target)”

    In silicoin silico hypergraph inference, not tested experimentally

    In Silico Generation of Absolute Biomedical Discoveries: Topological Inference of Post-Translational Modification Cascades and PubMed Automated Cross-Referencing

    Zenodo (CERN European Organization for Nuclear Research)Preprint

More on ULK1

Ascites

upin humans1

1 study
  1. Temsirolimus is associated with ascites in humans (disproportionality signal in FAERS reports; not in drug label).

    “the new positive signals not documented in the drug label were identified, including dehydration, pleural effusion, cardiac failure, and ascites”

    Humansdisproportionality signal in FAERS reports; not in drug labeln = 2,929

    Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database

    Naunyn-Schmiedeberg's archives of pharmacology

More on Ascites

Heart failure

upin humans1

1 study
  1. Temsirolimus is associated with heart failure in humans (disproportionality signal in FAERS reports; not in drug label).

    “the new positive signals not documented in the drug label were identified, including dehydration, pleural effusion, cardiac failure, and ascites”

    Humansdisproportionality signal in FAERS reports; not in drug labeln = 2,929

    Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database

    Naunyn-Schmiedeberg's archives of pharmacology

More on Heart failure

Pleural effusion

upin humans1

1 study
  1. Temsirolimus is associated with pleural effusion in humans (disproportionality signal in FAERS reports; not in drug label).

    “the new positive signals not documented in the drug label were identified, including dehydration, pleural effusion, cardiac failure, and ascites”

    Humansdisproportionality signal in FAERS reports; not in drug labeln = 2,929

    Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database

    Naunyn-Schmiedeberg's archives of pharmacology

More on Pleural effusion

Dehydration

upin humans1

1 study
  1. Temsirolimus is associated with dehydration in humans (disproportionality signal in FAERS reports; not in drug label).

    “the new positive signals not documented in the drug label were identified, including dehydration, pleural effusion, cardiac failure, and ascites”

    Humansdisproportionality signal in FAERS reports; not in drug labeln = 2,929

    Temsirolimus safety evaluation: real-world adverse event analysis from the FDA adverse event reporting system database

    Naunyn-Schmiedeberg's archives of pharmacology

More on Dehydration

Cerebral glucose metabolism

upin humans1

1 study
  1. Rapamycin is associated with cerebral glucose metabolism in humans (higher rapamycin blood concentrations).

    “Higher rapamycin blood concentrations correlated with increased [ 18 F]FDG SUVR in several regions, including the temporoparietal cortex.”

    Human trialhigher rapamycin blood concentrationsbrain

    Evaluation of rapamycin as a neuroprotective treatment in Alzheimer’s disease: a six-month single-arm open-label clinical pilot trial

    medRxivPreprint

More on Cerebral glucose metabolism

Terminal half-life

no changein humans1

1 study
  1. Rapamycin is associated with terminal half-life in humans (weekly oral dosing) (68.9 ± 13.6 h).

    “Estimate of terminal half-life (68.9 ± 13.6 h) aligned with previous studies.”

    Human trialweekly oral dosingweekly oraln = 13

    Pharmacokinetic analysis of intermittent rapamycin administration in early-stage Alzheimer's Disease

    GeroScience

More on Terminal half-life

All 31

Trials

35 of 1,344 about aging

Who is developing mTOR inhibitors?

3 companies: Novartis Pharmaceuticals, Chong Kun Dang Pharmaceutical and Astellas Pharma.

Companies
  • Novartis PharmaceuticalseverolimusPhase 4renal angiomyolipoma, pancreatic neuroendocrine tumor
  • Chong Kun Dang PharmaceuticaleverolimusPhase 4heart transplant
  • Astellas PharmarapamycinPhase 4kidney transplantation

Trial sponsors

Funding

10 grants since 2018

NIH Clinical CenterNational Institute on Aging$1.8MGrantová Agentura České RepublikyCZK 21.5M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Independent labs report mouse lifespan extension with rapamycin, but also shortening, and reduced senescence in human cells. Human trials report improved general health but mixed physical-function outcomes. Of registered trials, 28 concern aging; across all uses, 473 ended over a year ago without posted results or citing papers, and 361 are developer-sponsored.

  2. Summary rewritten as its findings changed.

    As it read before

    Independent labs report longer mouse lifespans with rapamycin but also reproduce lifespan shortening; other mouse studies find no change. Human trials report improved general health but mixed physical-function outcomes. Of registered trials, 26 concern aging; across all indications, 474 ended over a year ago without posted results or citing papers, 380 have developer sponsors, and four human papers declare Novartis ties.

  3. Summary rewritten as its findings changed.

    As it read before

    Independent labs report that rapamycin extends mouse lifespan, but also replicate lifespan shortening. A human trial reports improved lean tissue mass in women receiving 10 mg weekly. Of registered trials, 25 concern aging; across all uses, 474 ended over a year ago without posted results or citing papers, and 380 have developer sponsors.

  4. Summary rewritten as its findings changed.

    As it read before

    Independent labs report both lifespan extension and shortening in rapamycin-treated mice; other mouse studies report no lifespan effect. Independent labs also report improved cognition with everolimus in humans. Trial registrations include 19 about aging; across all uses, 401 trials ended over a year ago without posted results or citing papers, and some papers declare company ties.

  5. Summary rewritten as its findings changed.

    As it read before

    Independent labs report rapamycin extending mouse lifespan; fly lifespan results differ, and everolimus induces mouse senescence. A human trial reports topical rapamycin reducing skin p16INK4a; 19 trials concern aging, while 400 across all uses ended over a year ago without posted results or papers citing them. Some trials are developer-sponsored.

Latest

bioRxiv

Framework maps aging-related states in connective tissue cells

Tested across 20 independent fibroblast datasets, ECMExplainer used gene-activity comparisons to distinguish cell states and capture several processes related to aging.Tested across 20 independent fibroblast datasets, ECMExplainer used gene-activity comparisons to distinguish cell states and capture several processes related to aging.

Preprint: computational studyAI & data
Journal of the American Society of Nephrology

Kidney-risk variants linked to depleted calcium stores in cells

In cell experiments, kidney-risk protein variants entered an internal membrane more readily than the comparison variant, while rapamycin reduced protein levels and cell…In cell experiments, kidney-risk protein variants entered an internal membrane more readily than the comparison variant, while rapamycin reduced protein levels and cell harm.

Cell studyKidney

See all 2,411 papers on mTOR inhibitors